PDF download - Translumina

JACC Vol. 49, No. 12, 2007 Adriaenssens et al.
March 27, 2007:1265–71 Rapamycin Plus Estradiol-Eluting Stent
eration by locally delivered estrogen. Although the reendothelialization-promoting
properties of estrogen have
been demonstrated (11–13), they may not be sufficient to
counteract the inhibitory effects of rapamycin on the reendothelialization
process. Second, estrogen promotion of
the re-endothelialization process may depend on its concentration
at the site of vascular injury, but the optimal local
dose in humans is still not known (12). Finally, we cannot
exclude that a follow-up longer than 1 year might be
required to detect the advantages provided by estradiol
regarding prevention of late stent thrombosis after cessation
of thienopyridine therapy.
In conclusion, no apparent beneficial effect is obtained by
adding estradiol to a polymer-free RES during the first year
after the procedure.
Reprint requests and correspondence: Dr. Julinda Mehilli,
Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany.
E-mail: mehilli@dhm.mhn.de.
REFERENCES
1. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing
sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;
356:1030–9.
2. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in
drug-eluting coronary stents after discontinuation of antiplatelet therapy.
Lancet 2004;364:1519–21.
3. Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the
quantitative angiographic and volumetric intravascular ultrasound
analysis after nonpolymeric paclitaxel-eluting stent implantation: late
“catch-up” phenomenon from ASPECT study. J Am Coll Cardiol
2006;48:2432–9.
4. Wessely R, Kastrati A, Schömig A. Late restenosis in patients
receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med
2005;143:392–4.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.
6. Wessely R, Schömig A, Kastrati A. Sirolimus and paclitaxel on
polymer-based drug-eluting stents: similar but different. J Am Coll
Cardiol 2006;47:708–14.
7. Serry R, Penny WF. Endothelial dysfunction after sirolimus-eluting
stent placement. J Am Coll Cardiol 2005;46:237–8.
8. Kipshidze N, Dangas G, Tsapenko M, et al. Role of the endothelium
in modulating neointimal formation: vasculoprotective approaches to
attenuate restenosis after percutaneous coronary interventions. J Am
Coll Cardiol 2004;44:733–9.
9. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of
endothelial progenitor cells reduces neointima formation after vascular
injury. Circ Res 2003;93:e17–24.
10. Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery: the
next target in restenosis prevention. Circulation 2003;107:2635–7.
11. Chandrasekar B, Nattel S, Tanguay JF. Coronary artery endothelial
protection after local delivery of 17beta-estradiol during balloon
angioplasty in a porcine model: a potential new pharmacologic
approach to improve endothelial function. J Am Coll Cardiol 2001;
38:1570–6.
12. Chandrasekar B, Sirois MG, Geoffroy P, Lauzier D, Nattel S,
Tanguay JF. Local delivery of 17beta-estradiol improves reendothelialization
and decreases inflammation after coronary stenting in a
porcine model. Thromb Haemost 2005;94:1042–7.
13. Chandrasekar B, Tanguay JF. Local delivery of 17-beta-estradiol
decreases neointimal hyperplasia after coronary angioplasty in a porcine
model. J Am Coll Cardiol 2000;36:1972–8.
14. Dibra A, Kastrati A, Mehilli J, et al. Influence of stent surface
topography on the outcomes of patients undergoing coronary stenting:
Downloaded from
content.onlinejacc.org by guest on March 27, 2007
1271
a randomized double-blind controlled trial. Catheter Cardiovasc Interv
2005;65:374–80.
15. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima
formation by a novel drug-eluting stent system that allows for
dose-adjustable, multiple, and on-site stent coating. Arterioscler
Thromb Vasc Biol 2005;25:748–53.
16. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic
and clinical determinants of procedural outcome with angioplasty for
multivessel coronary disease. Implications for patient selection. Multivessel
Angioplasty Prognosis Study Group. Circulation 1990;82:
1193–202.
17. Mauri L, Hsieh W, Massaro JM, Ho KKL, D’Agostino R, Cutlip
DE. Stent thrombosis in randomized clinical trials of drug-eluting
stents. N Engl J Med 2007;356:1020–9.
18. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis.
Prog Cardiovasc Dis 1997;39:343–50.
19. Vanhoutte PM, Mombouli JV. Vascular endothelium: vasoactive
mediators. Prog Cardiovasc Dis 1996;39:229–38.
20. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF.
Estradiol accelerates reendothelialization in mouse carotid artery
through estrogen receptor-alpha but not estrogen receptor-beta. Circulation
2001;103:423–8.
21. Dai-Do D, Espinosa E, Liu G, et al. 17 beta-estradiol inhibits
proliferation and migration of human vascular smooth muscle cells:
similar effects in cells from postmenopausal females and in males.
Cardiovasc Res 1996;32:980–5.
22. White MM, Zamudio S, Stevens T, et al. Estrogen, progesterone, and
vascular reactivity: potential cellular mechanisms. Endocr Rev 1995;
16:739–51.
23. Khan MA, Liu MW, Singh D, et al. Long-term (three years) effect of
estrogen replacement therapy on major adverse cardiac events in
postmenopausal women after intracoronary stenting. Am J Cardiol
2000;86:330–3.
24. O’Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen
replacement therapy and restenosis after percutaneous coronary interventions.
J Am Coll Cardiol 1996;28:1111–8.
25. Schömig A, Kastrati A, Wessely R. Prevention of restenosis by systemic
drug therapy: back to the future? Circulation 2005;112:2759–61.
26. New G, Moses JW, Roubin GS, et al. Estrogen-eluting,
phosphorylcholine-coated stent implantation is associated with reduced
neointimal formation but no delay in vascular repair in a porcine
coronary model. Catheter Cardiovasc Interv 2002;57:266–71.
27. Abizaid A, Albertal M, Costa MA, et al. First human experience with
the 17-beta-estradiol-eluting stent: the Estrogen And Stents To
Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004;43:
1118–21.
28. Abizaid A. ETHOS I: no incremental benefit with estradiol eluting
stents. Paper presented at: Transcatheter Cardiovascular Therapeutics;
October 24, 2006; Washington, DC.
29. Airoldi F, Di Mario C, Ribichini F, et al. 17-beta-estradiol eluting
stent versus phosphorylcholine-coated stent for the treatment of native
coronary artery disease. Am J Cardiol 2005;96:664–7.
30. Tanguay JF, Labinaz M, Dzavik V, Colizza F. Local delivery of
17-beta-estradiol: 6-month results of the ESTRACURE trial. Paper
presented at: World Congress of Cardiology; September 5, 2006;
Barcelona, Spain.
31. Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by
a novel drug-eluting stent system with a dose-adjustable, polymer-free,
on-site stent coating. Eur Heart J 2005;26:1475–81.
32. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a
nonpolymer-based rapamycin-eluting stent versus a polymer-based
paclitaxel-eluting stent for the reduction of late lumen loss. Circulation
2006;113:273–9.
33. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and
intravascular ultrasound follow-up after implantation of sirolimuseluting
stents in human coronary arteries. Circulation 2003;107:381–3.
34. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native coronary artery.
N Engl J Med 2003;349:1315–23.
35. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind,
multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated
stent for treatment of native coronary artery
lesions: clinical and angiographic results of the ENDEAVOR II trial.
Circulation 2006;114:798–806.